Indaptus Therapeutics Q3 Loss Narrows to $1.0M on 82% R&D Cut

Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported a third-quarter 2026 net loss of approximately $1.0 million, narrowing from roughly $3.0 million a year earlier, as research and development spending fell 82% to about $0.3 million, the company announced on November 13, 2026. The immunotherapy developer ended September with approximately $30.6 million in cash, cash equivalents and short-term investments, and received roughly $3.5 million more in October tied to a September private placement that raised about $24.0 million in gross proceeds.

Context — Why Indaptus Rewrote Its Spending Plan

The quarter reflects a company that has moved from funding a clinical program to conserving cash while it searches for a new direction. Indaptus said the R&D decline came from lower clinical costs tied to its Decoy20 Phase 1 study and from lower payroll following headcount and base-salary reductions. Those same payroll cuts drove a 24% drop in general and administrative expenses.

Against that retrenchment, the company completed a September 8, 2026 private placement of 20,338,974 shares of common stock. The transaction closed October 16, 2026, with approximately $20.5 million received by September 30 and the remaining roughly $3.5 million arriving in October. Because the deal had not closed by quarter-end, the cash sits on the balance sheet as a liability rather than equity.

Chief Executive Officer and Chairman Junyi Dai framed the raise as the foundation for a pivot, saying the company's objective is to position Indaptus for its next phase of growth by pursuing innovative opportunities. The company's stated interest now centers on an early-stage neurotechnology and neural-network-based device aimed at certain sleep-related conditions.

That is a notable change in emphasis for a business whose public identity has been Decoy immunotherapy. Indaptus said it is evaluating the Decoy platform and existing therapeutic assets for potential licensing, partnership and other strategic opportunities, language that signals the legacy pipeline is now a candidate for monetization rather than internal advancement. The company also said it wants to better understand relationships among sleep, physical recovery, neurological function and immune status.

What triggered the shift is not spelled out. The report does not disclose whether a partner, regulator or internal review drove the decision, nor does it name any counterparty. What it does show is the arithmetic of a small-cap biotech that has cut its burn to buy time.

Data — The Numbers Behind the Narrower Loss

The magnitude of the cost reduction is the story. Research and development fell to approximately $0.3 million in Q3 2026 from approximately $1.5 million a year earlier, and to approximately $1.1 million for the first nine months from approximately $6.5 million. General and administrative expenses declined to approximately $0.9 million from approximately $1.1 million in the quarter, and to approximately $4.0 million from approximately $5.2 million over nine months.

Metric	Q3 2026	Q3 2025
Net loss	~$1.0M	~$3.0M
R&D expense	~$0.3M	~$1.5M
G&A expense	~$0.9M	~$1.1M
Net loss per share	~$0.01	~$2.98

The nine-month picture shows the same direction at larger scale. Net loss fell to approximately $5.4 million from approximately $12.7 million, and net loss per share improved to approximately $0.06 from approximately $18.48. Weighted average shares rose to 87,494,438 for the nine months from 689,174, a direct consequence of dilution across the period.

Two items complicate the clean cost story. The company booked a $410,154 warrant repricing charge in the nine-month period, and it recorded a $0.5 million termination fee tied to ending an ATM agreement, which partially offset the G&A savings. Net cash used in operating activities was approximately $10.4 million over nine months.

On the balance sheet, total assets rose to $31,211,985 from $9,310,168 at December 31, 2025. Total liabilities climbed to $20,879,859 from $6,158,575, almost entirely because of the $20,549,933 recorded as proceeds received pending share issuance.

Analysis — What the Pivot Means for INDP Holders

The second-order effect of the raise is a balance sheet that now looks unlike a typical pre-revenue biotech. Cash and short-term investments of approximately $30.6 million sit against a nine-month operating burn of roughly $10.4 million, and the certificates of deposit are redeemable on demand. Management said its current operating plan leaves sufficient liquidity for anticipated expenses and planned research activities.

The counter-argument is dilution. Authorized common stock rose to 1,000,000,000 shares from 200,000,000, issued and outstanding shares reached 133,242,324 from 2,167,324 at year-end, and 1,000,000 preferred shares outstanding at December 31, 2025 converted to zero. Existing holders absorbed substantial issuance, which is why per-share losses improved far more than the headline loss suggests the underlying business did.

The sector read-through is narrow but real. Immunotherapy peers with Phase 1 assets and thin cash cushions face the same choice Indaptus made: continue funding a single early-stage candidate or convert the asset into a licensing conversation. Indaptus chose both paths at once, keeping the Decoy platform alive for partnership while directing new capital toward a device concept that has no disclosed clinical data.

The limitation is that the sleep-device program is described only in aspirational terms. The report gives no trial design, no timeline, no regulatory correspondence and no budget. Positioning follows from that: this is a cash-and-optionality story for event-driven holders, not a data-catalyst story for clinical specialists, and the flow that matters is whatever the company does with the Decoy assets.

Outlook — What to Watch Next

The next hard datapoint is how quickly the new research direction produces anything verifiable. Indaptus said the scope and timing of the sleep-related activities will depend on scientific validation, strategic fit, market opportunities, available resources, regulatory considerations and other business factors, and that it hopes to explore a possible development pathway toward a future FDA submission. None of those milestones carries a date.

Investors should also watch the Decoy platform. The company said it is evaluating licensing, partnership and other strategic opportunities for the platform and existing therapeutic assets, which means any announcement on that front is the most likely near-term catalyst. The fourth-quarter report will be the first to show a full period of the new spending base and a clean equity treatment of the placement proceeds.

There are no analyst targets, price levels or index comparisons in the report, so none are offered here. The variables that matter are cash burn against the $30.6 million position, share count after the placement shares are formally issued, and whether the company names a partner, a device timeline or a clinical path.

Frequently Asked Questions

What does the Indaptus private placement mean for existing shareholders?

It strengthens liquidity but dilutes ownership. The company issued 20,338,974 shares and raised approximately $24.0 million in gross proceeds, with about $20.5 million received by September 30 and roughly $3.5 million in October. Authorized shares rose to 1,000,000,000 from 200,000,000, and outstanding shares reached 133,242,324 from 2,167,324 at December 31, 2025. Holders should expect the placement shares to move from a liability line into equity once formally issued.

Why did Indaptus research and development costs fall so sharply?

The company attributed the decline to lower clinical costs related to the Decoy20 Phase 1 study and to lower payroll and related expenses following reductions in headcount and base salaries. R&D fell 82% in the quarter to approximately $0.3 million and 83% over nine months to approximately $1.1 million. That is a reduction in activity, not a reclassification, and it leaves the legacy pipeline dependent on external partnership to advance.